Free Newsletter
A new strategy for fighting melanoma
The notion that cancer stem cells are responsible for much of the worst damage associated with the disease took another step forward with the release of a new study from Harvard Medical School that identified antibodies that could be used to slow melanoma, the most lethal form of cancer. Co-author George Murphy noted that their work shows that cancer stem cells can be effectively targeted, offering a new therapeutic approach for a range of cancers. There's been a growing belief that cancer cells aren't all made alike, with a particular emphasis on stem cells that appear to be resistant to chemotherapy. The next step is to take the animal studies into man. Researchers suggested that this approach toward fighting cancer could become common in just a few years.
"If this works with melanoma, this may also work with other tumors that are notoriously difficult to treat" once they have spread, Dr. Murphy told the Boston Globe.
- read the article in the Boston Globe
Related Articles:
Synta therapy slows spread of melanoma. Report
Researchers prompt melanoma to make sounds. Report
Gene therapy cures two of advanced melanoma. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: